ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

HRS-9563

A development code. Also written as “HRS-9563 Injection”.

Its studies are mostly in Hypertension, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Dec 9, 20251 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningphase 2since Dec 9, 2025Dec 9, 2025Dec 2026phase 2 · NCT07297797

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2025First study: phase 2 study in Mild to Moderate HypertensionFirst studyNCT07297797 · 238 enrolled · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Mild to Moderate HypertensionNCT07297797

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07297797Mild to Moderate Hypertension · China2Active, not recruitingDec 2026238

How it is read

Names in the registry

  • “HRS-9563 Injection”, 1 entry

Codes read as this program: HRS9563.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.